These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 36047134)
21. First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. Quhal F; Mori K; Bruchbacher A; Resch I; Mostafaei H; Pradere B; Schuettfort VM; Laukhtina E; Egawa S; Fajkovic H; Remzi M; Shariat SF; Schmidinger M Eur Urol Oncol; 2021 Oct; 4(5):755-765. PubMed ID: 33757737 [TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of immune checkpoint inhibitors in elderly patients with metastatic renal cell carcinoma. Nemoto Y; Ishihara H; Nakamura K; Tachibana H; Fukuda H; Yoshida K; Kobayashi H; Iizuka J; Shimmura H; Hashimoto Y; Tanabe K; Kondo T; Takagi T Int Urol Nephrol; 2022 Jan; 54(1):47-54. PubMed ID: 34704214 [TBL] [Abstract][Full Text] [Related]
23. [The analysis of cytokines in cerebrospinal fluid (CSF) in two cases of non-herpetic acute limbic encephalitis (NHALE)]. Takahashi T; Kamei S; Miki K; Ogawa K; Mizutani T Rinsho Shinkeigaku; 2003 Apr; 43(4):162-9. PubMed ID: 12884825 [TBL] [Abstract][Full Text] [Related]
24. Prognostic Impact of Early Treatment Interruption of Nivolumab Plus Ipilimumab Due to Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma: A Multi-Institution Retrospective Study. Ishihara H; Nemoto Y; Nakamura K; Ikeda T; Tachibana H; Fukuda H; Yoshida K; Kobayashi H; Iizuka J; Shimmura H; Hashimoto Y; Takagi T; Ishida H; Kondo T; Tanabe K Target Oncol; 2021 Jul; 16(4):493-502. PubMed ID: 34173936 [TBL] [Abstract][Full Text] [Related]
25. Vogt-Koyanagi-Harada's disease presenting polymorphonuclear pleocytosis in the cerebrospinal fluid at the early active stage. Kato Y; Kurimura M; Yahata Y; Tajima K; Kato T Intern Med; 2006; 45(12):779-81. PubMed ID: 16847368 [TBL] [Abstract][Full Text] [Related]
26. [A case of meningoencephalitis that developed during nivolumab use]. Suzuki Y; Sakurai K; Uchino K; Inoue T; Takahashi T; Hasegawa Y; Yamano Y Nihon Ronen Igakkai Zasshi; 2021; 58(4):624-629. PubMed ID: 34880182 [TBL] [Abstract][Full Text] [Related]
27. Nivolumab induced hypophysitis in an advanced RCC patient. Korkmaz Yilmaz M; Gulturk I; Tacar SY; Yilmaz M J Oncol Pharm Pract; 2022 Apr; 28(3):759-762. PubMed ID: 35006033 [TBL] [Abstract][Full Text] [Related]
28. Fatal enteric plexus neuropathy after one dose of ipilimumab plus nivolumab: a case report. Appelbaum J; Wells D; Hiatt JB; Steinbach G; Stewart FM; Thomas H; Nghiem P; Kapur RP; Thompson JA; Bhatia S J Immunother Cancer; 2018 Aug; 6(1):82. PubMed ID: 30170630 [TBL] [Abstract][Full Text] [Related]
29. Dual immune checkpoint inhibition in metastatic renal cell carcinoma: Editorial re.: Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced RCC: extended 4-year follow-up of the phase III CheckMate 214 trial. Schmidinger M; Shariat SF; Fajkovic H ESMO Open; 2021 Feb; 6(1):100035. PubMed ID: 33421736 [No Abstract] [Full Text] [Related]
30. Autoimmune encephalitis related to nivolumab followed by tumor regression. Mysler SJ; Perazzo F; Mandó P Medicina (B Aires); 2023; 83(3):479-483. PubMed ID: 37379548 [TBL] [Abstract][Full Text] [Related]
31. Pulse corticosteroid therapy in the treatment of steroid-refractory immune checkpoint inhibitor-related pneumonitis: Case report and review. Lai KC; Hsiao YH; Chen SC Front Immunol; 2022; 13():994064. PubMed ID: 36119082 [TBL] [Abstract][Full Text] [Related]
32. Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study. Hammers HJ; Plimack ER; Infante JR; Rini BI; McDermott DF; Lewis LD; Voss MH; Sharma P; Pal SK; Razak ARA; Kollmannsberger C; Heng DYC; Spratlin J; McHenry MB; Amin A J Clin Oncol; 2017 Dec; 35(34):3851-3858. PubMed ID: 28678668 [TBL] [Abstract][Full Text] [Related]
33. Safe and effective use of nivolumab plus ipilimumab in a patient with metastatic clear-cell renal cell carcinoma with sarcomatoid dedifferentiation and end stage renal disease on hemodialysis. Shaw LK; Wiele AJ; Sircar K; Wood CG; Msaouel P Cancer Treat Res Commun; 2021; 27():100349. PubMed ID: 33725559 [TBL] [Abstract][Full Text] [Related]
34. Early 3+3 Trial Dose-Escalation Phase I Clinical Trial Design and Suitability for Immune Checkpoint Inhibitors. Rahma OE; Reuss JE; Giobbie-Hurder A; Shoja E Razavi G; Abu-Shawer O; Mehra P; Gupta S; Simon R; Khleif SN Clin Cancer Res; 2021 Jan; 27(2):485-491. PubMed ID: 33082209 [TBL] [Abstract][Full Text] [Related]
36. Myositis as an adverse event of immune checkpoint blockade for cancer therapy. Shah M; Tayar JH; Abdel-Wahab N; Suarez-Almazor ME Semin Arthritis Rheum; 2019 Feb; 48(4):736-740. PubMed ID: 29909921 [TBL] [Abstract][Full Text] [Related]
37. First case of hemophagocytic lymphohistiocytosis secondary to cabozantinib with checkpoint inhibitors. Azari AE; Stratton R; Singh A Rheumatology (Oxford); 2021 May; 60(5):e167-e168. PubMed ID: 33280022 [No Abstract] [Full Text] [Related]
38. Cerebrospinal fluid interleukin-6 concentration in patients with purulent, bacterial meningitis - own observations. Kępa L; Oczko-Grzesik B; Boroń-Kaczmarska A Przegl Epidemiol; 2014; 68(4):645-9. PubMed ID: 25848784 [TBL] [Abstract][Full Text] [Related]
39. Durable response after immunotherapy discontinuation for delayed and severe immune-related adverse events: a case report. Pesola G; Murianni V; Rebuzzi SE; Banna GL; Cerbone L; Catalano F; Borea R; Gandini A; Cremante M; Puglisi S; Trovato F; Fornarini G Immunotherapy; 2021 Dec; 13(17):1379-1386. PubMed ID: 34743545 [TBL] [Abstract][Full Text] [Related]
40. Immune checkpoint inhibitor therapy-associated encephalitis: a case series and review of the literature. Stuby J; Herren T; Schwegler Naumburger G; Papet C; Rudiger A Swiss Med Wkly; 2020 Nov; 150():w20377. PubMed ID: 33232507 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]